NVCN News and Press, Neovasc Inc.

Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...

2023-04-03 00:36:41 ET Neovasc press release ( NASDAQ: NVCN ): FY GAAP EPS of -$15.07. Revenue of $3.81M (+49.4% Y/Y). For further details see: Neovasc GAAP EPS of -$15.07, revenue of $3.81M

VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...

2023-03-10 10:28:14 ET Summary I generally like CVR and this is no exception. The CVR is not a sure thing but it does appear to be undervalued by the market. Shareholders have voted yes on the deal and I expect it to close very soon. Several biotech mergers/tenders w...

VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...

VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - February 01, 2023 -   Neovasc, Inc.  (“Neovasc” or “the Company”) ( NASDAQ  ,   TSX  : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”)...

Shockwave Medical ( NASDAQ: SWAV ) reported preliminary Q4 revenue and outlook for FY2023 which seen above analysts estimates. In addition, Shockwave announced the acquisition of Neovasc ( NASDAQ: NVCN ) for an enterprise value of ~$100M plus certain contingent payment...

Shockwave Medical ( NASDAQ: SWAV ) is acquiring Neovasc ( NASDAQ: NVCN ) for an enterprise value of ~$100M plus certain contingent payments. Canada-based medical device maker Neovasc is developing a minimally invasive treatment for refractory angina —  a t...

Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Sh...

VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entere...